NASDAQ · CLPT

ClearPoint Neuro, Inc.

$14.60 +$0.48 (+3.40%) 1D After hours

Key Metrics

$423.45M
Market cap
P/E · TTM
$40.61M
Revenue · TTM
−$29.07M
Net income
EPS · TTM $-1.05
Dividend yield
Free cash flow −$26.70M
Beta · 1Y 2.17
EBITDA · TTM −$25.68M
Gross margin 62.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 17
    The stock moved +26.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 17
  • Mar 30
    From its Feb 25 high, the share price fell 43%.

    Peak close $15.16 on Feb 25; trough close $8.66 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -43%
  • Mar 2
    The stock moved -22.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$423.45M
Enterprise value$437.50M
Shares outstanding30.0M
52-wk range$8.27 – $30.10
Avg volume · 20D314.2K
Net cash −$14.05M
Book value / share$0.68
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About ClearPoint Neuro, Inc.
IPO dateMay 18, 2012
Employees172

ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S10.43
P/FCF
EV/EBITDA
EV/Sales10.77
Graham №

Profitability

Gross 62.3%
Operating -65.2%
Net -71.6%
FCF -65.8%
ROE / ROIC -131.4% · -80.6%

Financial Health

Current ratio5.79
Quick ratio4.88
Debt / equity2.63
Debt / EBITDA -1.93
Net cash −$14.05M
Working capital$45.40M

Cash Flow · TTM

Operating CF −$25.72M
Capex −$984.00K
Free cash flow −$26.70M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

0.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings